Katherine A. High
2017
In 2017, Katherine A. High earned a total compensation of $2.5M as President and Head of Research and Development at Spark Therapeutics, a 15% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $261,984 |
|---|---|
| Salary | $448,654 |
| Stock Awards | $1,736,802 |
| Other | $38,942 |
| Total | $2,486,382 |
High received $1.7M in stock awards, accounting for 70% of the total pay in 2017.
High also received $262K in non-equity incentive plan, $448.7K in salary and $38.9K in other compensation.
Rankings
In 2017, Katherine A. High's compensation ranked 4,451st out of 14,666 executives tracked by ExecPay. In other words, High earned more than 69.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,451 out of 14,666 | 70th |
Division Manufacturing | 1,566 out of 5,768 | 73rd |
Major group Chemicals And Allied Products | 450 out of 2,074 | 78th |
Industry group Drugs | 345 out of 1,730 | 80th |
Industry Biological Products, Except Diagnostic Substances | 65 out of 316 | 79th |
Source: SEC filing on April 20, 2018.
High's colleagues
We found five more compensation records of executives who worked with Katherine A. High at Spark Therapeutics in 2017.
2017
Jeffrey Marrazzo
Spark Therapeutics
Chief Executive Officer
2017
Daniel Faga
Spark Therapeutics
Chief Business Officer
2017
Stephen Webster
Spark Therapeutics
Chief Financial Officer
2017
Joseph Barge
Spark Therapeutics
Chief Legal Officer
2017
John Furey
Spark Therapeutics